Sunday, June 04, 2017 8:43:55 PM
I absolutely love Afrezza. It has been a game changer for me. 1st September 2015 was my first inhale. I have read here people talking about energy like nothing else having ate a carbohydrate meal, no spikes, the idea of first phase insulin stabilizing BG levels. I could not believe the change that happened in my body. I had a number of health issues before Afrezza which disappeared within 24 hours of my first inhalation.m It's not a miracle cure and requires effort but the upshot is amazing and worth the initial time input. Basal insulin may need to be increased. MIne is Tresiba. I am awaiting to get more Afrezza as I am currently in the UK and it is not available here. Presently I use Porcine Neutral but the onset is one hour and the tail is 10 hours and so I have had some sneaky lows that have incapacitated me. Here are the benefits of Afrezza. It needs more noise to be created about it and diabetics to demand that they can try it.
Advantages
1. My energy levels soared on Afrezza. I have never felt this good in all my life. I am not tired all the time. I have more energy and I am definitely more productive.
2. I am not having to micro-manage diabetes.
3. I am prescribed Lyrinel for excessive sweating as I have suffered from this for well almost 20 years and it’s detrimentally affected me over the last 10. I have had botox to provide temporary relief and I have needed to use aluminium chloride salts to control it(Odaban). My sweating has stopped completely on Afrezza. I have stopped taking Lyrinel completely.
4. I have much more feeling in the tips of my fingers and my toes. I have never had an issue with this but my sense of touch in my extremities has improved. I am not saying it was bad to start off with. In fact I have never mentioned this and my pulses and circulation have always been good but there is a huge difference in sensation for me.
5. I do not get pains in my calves and shins. This was very noticeable and I have found that co-codamol helps. I have stopped requesting co-codamol in my repeat prescription as the pain is no more.
6. My docs are amazed at the improvement in my retinopathy due to reduced glycaemic variability and a more stable profile.
Advantages
1. My energy levels soared on Afrezza. I have never felt this good in all my life. I am not tired all the time. I have more energy and I am definitely more productive.
2. I am not having to micro-manage diabetes.
3. I am prescribed Lyrinel for excessive sweating as I have suffered from this for well almost 20 years and it’s detrimentally affected me over the last 10. I have had botox to provide temporary relief and I have needed to use aluminium chloride salts to control it(Odaban). My sweating has stopped completely on Afrezza. I have stopped taking Lyrinel completely.
4. I have much more feeling in the tips of my fingers and my toes. I have never had an issue with this but my sense of touch in my extremities has improved. I am not saying it was bad to start off with. In fact I have never mentioned this and my pulses and circulation have always been good but there is a huge difference in sensation for me.
5. I do not get pains in my calves and shins. This was very noticeable and I have found that co-codamol helps. I have stopped requesting co-codamol in my repeat prescription as the pain is no more.
6. My docs are amazed at the improvement in my retinopathy due to reduced glycaemic variability and a more stable profile.
Recent MNKD News
- MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval • GlobeNewswire Inc. • 05/29/2026 06:00:00 PM
- MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes • GlobeNewswire Inc. • 05/29/2026 04:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2026 12:37:11 PM
- MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems • GlobeNewswire Inc. • 05/27/2026 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2026 01:10:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2026 01:00:01 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2026 12:56:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2026 12:52:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2026 12:51:22 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2026 12:50:21 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2026 12:49:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2026 12:48:42 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2026 12:48:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2026 12:47:16 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 09:17:49 PM
- Form 144/A - Report of proposed sale of securities: [Amend] • Edgar (US Regulatory) • 05/14/2026 08:51:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 12:30:04 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 12:30:03 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/12/2026 08:34:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/12/2026 08:34:39 PM
- The $59B Quiet Shift Reshaping How Patients Access Care • PR Newswire (Canada) • 05/12/2026 02:30:00 PM
- The $59B Quiet Shift Reshaping How Patients Access Care • PR Newswire (US) • 05/12/2026 02:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2026 08:05:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 08:03:30 PM
- MannKind Reports First Quarter 2026 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/06/2026 08:01:00 PM
